Results 201 to 210 of about 13,411 (297)

Smart Nanodelivery Systems for Immunometabolic Modulation in Osteoarthritis

open access: yesExploration, EarlyView.
Smart nanodelivery systems deliver therapeutic payloads across the cartilage matrix to ensure their sustained accumulation within chondrocytes at sites of injury. By targeting specific molecular targets and signaling pathways, these platforms modulate the pathological synovium‐cartilage axis to restore immunometabolic homeostasis and drive tissue ...
Qirui Zhao   +20 more
wiley   +1 more source

Incidence and Site‐Specific Risk Factors of Jaw Osteoradionecrosis for Head and Neck Patients in the IMRT/VMAT Era: Evidence From a Large, Hospital‐Based Cohort

open access: yesHead &Neck, EarlyView.
ABSTRACT Purpose Osteoradionecrosis (ORN) of the jaw remains a serious late complication of head and neck cancer (HNC) radiotherapy. Although intensity‐modulated radiotherapy (IMRT) and volumetric‐modulated arc radiotherapy (VMAT) are expected to reduce ORN risk, large real‐world data in the modern era are limited.
Fang‐Yu Wu   +3 more
wiley   +1 more source

Paradigm shift in the application of patient contact shielding: a balancing act between tradition and progress. [PDF]

open access: yesEur Radiol
Schürmann T   +11 more
europepmc   +1 more source

The Role of Multicancer Early Detection Tests in Head and Neck Squamous Cell Carcinoma: A Case Series

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) lacks an established screening program, and most cases are diagnosed at advanced stages. Multi‐cancer early detection (MCED) blood‐based assays represent a promising approach, yet real‐world clinical experience with MCED‐identified HNSCC remains limited.
Abhinav Talwar   +3 more
wiley   +1 more source

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

open access: yesInternational Journal of Cancer, EarlyView.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim   +22 more
wiley   +1 more source

Risk–Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta‐Analysis

open access: yesInternational Journal of Cancer, EarlyView.
The therapeutic status of drug administration in phase 2 cancer trials is ambiguous, as these studies test efficacy without strong evidence of clinical benefit. Nonetheless, patients face meaningful risks. This review compared efficacy and safety of monotherapy drugs in phase 2 and phase 3 trials across six cancer types.
Charlotte Ouimet   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy